Key result
Higher multimodal biological age acceleration linked to ~40% greater odds of prevalent CVD per SD.
Why the study?
Most biological age models rely on systemic and unimodal indices, leaving the added value of organ-specific and multimodal information for assessing organ-specific disease associations unclear.
Does biological age acceleration derived from multimodal models associate with prevalent cardiovascular disease in adults?
Cross-Sectional (n=1,830)
No
Does biological age acceleration derived from multimodal models associate with prevalent cardiovascular disease in adults?
Multimodal biological age models integrating echocardiographic and blood-based biomarkers provide complementary information and are significantly associated with prevalent cardiovascular disease.
Answers are grounded in this paper and cite their sources.
May support aging biomarker integration in CVD risk models; leaves open prospective validation of predictive utility.
Background Biological ages capture aging signatures associated with aging-related outcomes, but most models use systemic and unimodal indices. The added value of organ-specific and multimodal information for assessing organ-specific disease associations remains unclear. Methods We enrolled 1,830 participants (77.81% male; age 55.87 ± 11.07 years) undergoing blood chemistry testing and echocardiography. Cardiac, systemic, and multimodal biological age models were trained using supervised machine learning with 20-fold cross-validation to predict chronological age from LASSO-selected variables among 15 echocardiographic indices, 73 blood-based indices, or their combination. Biological age acceleration (BAA) was derived using modality-specific age-bias correction functions fitted in the apparently healthy reference cohort and standardized before analysis. Associations between BAA and prevalent cardiovascular disease (CVD; ICD-10 I00–I99) were evaluated using multivariable logistic regression. Models were developed in 937 apparently healthy participants; CVD analyses compared 810 cases with 1,020 CVD-negative participants. Results Cardiac biological age showed moderate accuracy (mean absolute error [MAE] = 6.08 years; R 2 = 0.34), with A1 (late diastolic transmitral flow velocity) and septal e′ (early diastolic mitral annular velocity) as the leading SHAP contributors. Systemic biological age performed better (MAE = 4.60 years; R 2 = 0.65), with estimated glomerular filtration rate and creatinine as the leading contributors. Cardiac BAA showed a numerically larger association with prevalent CVD than systemic BAA (odds ratio [OR] = 1.36, 95% confidence interval [CI] 1.23–1.52 vs. OR = 1.31, 95% CI 1.20–1.43). Cardiac and systemic biological ages showed partial overlap ( R 2 = 0.25). The multimodal model achieved the best age-prediction performance (MAE = 4.29 years; R 2 = 0.70) and was associated with prevalent CVD (OR = 1.40, 95% CI 1.28–1.53). Subtype-specific associations were broadly directionally consistent; significance was reached for hypertension, whereas estimates for smaller subtypes remained imprecise. Conclusions Cardiac and systemic biological age models captured complementary aging information and showed distinct strengths in chronological-age estimation and cross-sectional CVD assessment. The multimodal model achieved the lowest MAE and highest R 2 , supporting the complementary value of multimodal integration for biological aging assessment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cross-sectional in Cardiovascular disease (n=1,830). Multimodal biological age acceleration (BAA) vs. Lower BAA (per 1-SD increase) was evaluated on Prevalent cardiovascular disease (CVD) (OR 1.40, 95% CI 1.28-1.53, p=<0.001). A 1-SD increase in multimodal biological age acceleration, integrating cardiac and systemic biomarkers, was associated with higher odds of prevalent cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: